Revenue: As of FY2027 Q1, the actual value is USD 0.

EPS: As of FY2027 Q1, the actual value is USD -0.75, missing the estimate of USD -0.6319.

EBIT: As of FY2027 Q1, the actual value is USD -153.22 M.

Immunovant, Inc. filed a Form 8-K on August 6, 2026, announcing its financial results for the fiscal first quarter ended June 30, 2026, via a press release furnished as Exhibit 99.1. However, the Form 8-K document itself does not detail any specific financial or operational metrics, such as segment revenue, net income, gross margin, operating profit, operating costs, cash flow, or other company-specific financial indicators. Additionally, the document does not include any forward-looking statements or guidance regarding future financial performance or operational outlook.